{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:35:00Z","timestamp":1782711300408,"version":"3.54.5"},"reference-count":39,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T00:00:00Z","timestamp":1472428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To study trends in use of antidepressants (ADs) by adolescents, and psychiatric morbidity and use of other psychotropic drugs as a measure of psychiatric comorbidity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>One\u2010year prevalence of <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> drug use was analyzed for 13\u2010 to 17\u2010year\u2010old Norwegians during 2004\u20132013. Use of other psychotropic drugs and specialist healthcare services was analyzed for incident <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> users in 2012, using linked data from the Norwegian Prescription Database and the Norwegian Patient Register.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 1\u2010year prevalence of <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> drug use increased from 6.4\/1000 to 9.1\/1000 during 2004\u20132013, with the steepest increase from 2010, particularly among girls. The highest prevalence was found in 17\u2010year\u2010old girls (17.8\/1000 in 2010, 27.5\/1000 in 2013). Of incident <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> drug users in 2012, 84.4% had been in contact with specialist health care. As the first drug, 78.4% were prescribed a selective serotonin reuptake inhibitor. The most common types of other psychotropic drugs were melatonin (24.6%), antipsychotic drugs (13.2%), stimulants (8.8%), and anxiolytics (6.0%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Use of <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>s among adolescents has increased over the last 3\u20134 years, particularly among 16\u2010 to 17\u2010year\u2010old girls. A total of 85% of incident users had been in contact with specialist health care, which may indicate that drug\u2010therapy is used by adolescents with more severe symptoms.<\/jats:p><\/jats:sec>","DOI":"10.1111\/acps.12633","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T17:26:55Z","timestamp":1472491615000},"page":"420-429","source":"Crossref","is-referenced-by-count":20,"title":["Antidepressant drug use among adolescents during 2004\u20132013: a population\u2010based register linkage study"],"prefix":"10.1111","volume":"134","author":[{"given":"I.","family":"Hartz","sequence":"first","affiliation":[{"name":"Faculty of Public health Hedmark University College Elverum Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Skurtveit","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health Oslo Norway"},{"name":"Norwegian Centre for Addiction Research University of Oslo Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Hjellvik","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Furu","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Nesv\u00e5g","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health Oslo Norway"},{"name":"Department of Psychiatric Research Diakonhjemmet Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Handal","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8,29]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"2470","article-title":"[Prescription of selective serotonin reuptake inhibitors 1990\u20132004]","volume":"125","author":"Bramness JG","year":"2005","journal-title":"Tidsskr Nor Laegeforen"},{"key":"e_1_2_7_3_1","unstructured":"European Medicines Agency (EMA).European Medicines Agency finalizes review of antidepressants in children and adolescents. Report: EMEA\/CHMP\/128918\/2005. Available fromhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/SSRI_31\/WC500013082.pdf(accessed 8 June 2015)."},{"key":"e_1_2_7_4_1","unstructured":"US Food and Drug Administration.FDA launches a multi\u2010pronged strategy to strengthen safeguards for children treated with antidepressant medications.2004. Available fromhttp:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2004\/ucm108363.htm(accessed 18 March 2015)."},{"key":"e_1_2_7_5_1","first-page":"2653","article-title":"Use of antidepressants among children and adolescents\u2013did the warnings lead to fewer prescriptions?","volume":"127","author":"Bramness J","year":"2007","journal-title":"Tidsskr Nor Laegeforen"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1430"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3181ef9d2b"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i65"},{"key":"e_1_2_7_9_1","first-page":"CD007504","article-title":"Newer generation antidepressants for depressive disorders in children and adolescents","volume":"11","author":"Hetrick SE","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.10.1132"},{"key":"e_1_2_7_11_1","volume-title":"Recommendations for child and adolescent psychiatry","author":"Haaland G","year":"2010"},{"key":"e_1_2_7_12_1","unstructured":"National Institute for Health and Care Excellence (NICE).Depression in children and young people: Identification and management in primary community and secondary care(NICE Clinical Guideline No. 28).2015. Available fromwww.nice.org.uk\/guidance\/cg28(accessed 1 March 2016)."},{"key":"e_1_2_7_13_1","unstructured":"National Institute for Health and Care Excellence (NICE).Compulsive disorder: core interventions in the treatment of obsessive\u2013compulsive disorder and body dysmorphic disorder(NICE Clinical Guideline No. 31).2006. Available fromhttps:\/\/www.nice.org.uk\/guidance\/cg31\/(accessed 1 March 2016)."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2013.11.001"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0014-8"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-0716-x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-014-0523-1"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12155"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.02.001"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1753-2000-2-26"},{"key":"e_1_2_7_21_1","unstructured":"The Norwegian Prescription Database National Institute of Public Health. Available fromhttp:\/\/www.fhi.no\/eway\/default.aspx?pid=233&trg=MainArea_5661&MainArea_5661=5565:0:15 3791:1:0:0:::0:0&MainLeft_5565=5544:50553::1:5569:10:::0:0(accessed 15 June 2015)."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2009.00494.x"},{"key":"e_1_2_7_23_1","volume-title":"ATC classification index with DDDs","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2016"},{"key":"e_1_2_7_24_1","first-page":"2194","article-title":"[Is alimemazine a suitable sleeping agent for children?]","volume":"128","author":"Slordal L","year":"2008","journal-title":"Tidsskr Nor Laegeforen"},{"key":"e_1_2_7_25_1","unstructured":"The Norwegian Patient Register. Available fromhttp:\/\/helsedirektoratet.no\/kvalitet-planlegging\/norsk-pasientregister-npr\/Sider\/default.aspx(accessed 20 June 2015)."},{"key":"e_1_2_7_26_1","first-page":"65","article-title":"Norsk pasientregister: administrativ database med mange forskningsmuligheter","volume":"14","author":"Bakken IJ","year":"2004","journal-title":"Nor Epidemiol"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2009.0003"},{"key":"e_1_2_7_28_1","first-page":"CD008324","article-title":"Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents","volume":"11","author":"Cox GR","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2015.01.015"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-015-0153-1"},{"key":"e_1_2_7_31_1","unstructured":"Hedmark County Council.Public health in Hedmark County \u2013 the youth health survey 2009. Available fromhttp:\/\/www.hedmark.org\/Hedmark-fylkeskommune\/Om-fylkeskommunen\/Fag-stab-og-serviceenheter\/Strategisk-stab\/Folkehelse\/Statistikk-og-fakta-folkehelse\/Ungdomsundersoekelsen-2009(accessed 8 March 2015)."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.12381"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2010.05.017"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/1753-2000-5-28"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10802-008-9268-y"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1037\/0012-1649.35.1.232"},{"key":"e_1_2_7_37_1","unstructured":"US Food and Drug Administration (FDA).Drug safety communication posted 03\/28\/2012: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. FDA Web site. Available fromhttp:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm297391.htm(accessed 19 March 2015)."},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13r08672"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-014-0088-y"},{"key":"e_1_2_7_40_1","first-page":"CD002317","article-title":"Tricyclic drugs for depression in children and adolescents","volume":"6","author":"Hazell P","year":"2013","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Facps.12633","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acps.12633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/acps.12633","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acps.12633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:10:47Z","timestamp":1695492647000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acps.12633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,29]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/acps.12633"],"URL":"https:\/\/doi.org\/10.1111\/acps.12633","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,29]]}}}